Sean007, good question about Vyera filing for Chap

Sean007, good question about Vyera filing for Chapter 11. I found the info below in a CYDY filing in EDGAR:

Quote:

---

In December 2019, the Company entered into a Commercialization and License Agreement, and Supply Agreement (together the “License Agreements”) with Vyera Pharmaceuticals, LLC (“Vyera”) under which the Company granted Vyera an exclusive royalty-bearing license to commercialize pharmaceutical preparations containing leronlimab for treatment of HIV in the United States. The License Agreements gave Vyera the right to assign its rights and obligations under the License Agreements to an affiliate of Vyera. In October 2020, Vyera assigned the License Agreements to SevenScore Pharmaceuticals, which in turn, in December 2021, assigned them to Regnum Corp. Vyera, SevenScore and Regnum are each controlled by their parent Phoenixus AG.

---

Above is on page F-29 for a 424B3 (Prospectus) filed 2-22-24. You can see it at this link.
https://www.sec.gov/Archives/edgar/data/11756...x424b3.htm

The following is on page 7 of Regnum’s 10-Q for the 3 months ending 3/31/23 (which is their latest 10-Q):

Quote:

---

Regnum Corp. (the “Company” or “Regnum,” “we,” “us,” “our” and similar terminology) was incorporated on March 31, 2016, under the laws of the State of Nevada. The Company was originally formed for the primary business purpose of servicing the demand for premium entertainment content and becoming a depository of unpublished intellectual properties for resale with focus on achieving profitability and sustaining business growth. Following the acquisition by Phoenixus AG, a Swiss holding company (“Phoenixus”) of approximately 99% of the shares of common stock, par value $0.001 per share, of the Company (the “Common Stock”) on April 7, 2021, the Company’s prior business model was abandoned and the Company is currently focused on developing and commercializing therapeutics that treat rare and infectious diseases, specifically in populations that are neglected or face adherence challenges.

The Company submitted a Company Related Action Notification, in accordance with Financial Industry Regulatory Authority (“FINRA”) Rule 6490 (the “Corporate Action Notice”) on October 20, 2021, in connection with a proposed change of the Company’s name to “Rovida Therapeutics, Inc.” and change the Company’s trading symbol, as well as to redomicile of the Company from the state of Nevada to the state of Delaware (the “Corporate Actions”). The Corporate Actions were approved by the board of directors of the Company on October 21, 2021, and were approved by consent of Phoenixus as majority stockholder on October 21, 2021. While the Corporate Actions were denied by FINRA in April 2022 (and subsequently denied on appeal in August 2022) due to Phoenixus’s former association with Martin Shkreli (“Shkreli" , the Company may revisit the Corporate Actions at such time as factual circumstances relating to Shkreli and Phoenixus merit.

---

https://www.sec.gov/Archives/edgar/data/17163...mp_10q.htm

The following is from an 8-K dated 5/30/23 (Regnum’s last filing in EDGAR):

Quote:

---

On May 23, 2023, Anne Kirby provided formal notice of her resignation as Chief Executive Officer and as the sole member of the board of directors of Regnum Corp. (the “Company”). Ms. Kirby’s resignation was for personal reasons and not a result of a disagreement relating to the Company’s operations, policies or practices. The Company and its majority shareholder have begun the process to fill the board and officer vacancies with suitable candidates.

---

https://www.sec.gov/Archives/edgar/data/17163...gmp_8k.htm

I searched in EDGAR for reports on Phoenixus AG. It is a Swiss corporation and there are only 2 documents, both of which are beneficial ownership reports with the last one dated 1/11/21.

It is interesting that Vyera filed for Chapter 11 on 5/10/23 and Anne Kirby resigned as CEO and sole board member of Regnum on 5/23/23. Question for the lawyers on this board: if the FDA approves Livimmune instead of Leronlimab, would that negate this agreement?

Lots of verbiage above, but I don’t have a clue what is going on. I hope Dr. Jay and his team will update us on this issue at some point down the road.